Ibrahim  Mohamed

Dr. Ibrahim Mohamed

Department of Pediatrics-Neonatology, CHU Sainte-Justine, Université de Montréal, Montréal, Canada
orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2017 in Clinics in Perinatology
Verified
Journal Article
Closed access
ANAnne Monique Nuyt
Anne Monique Nuyt
JLJean-Claude Lavoie
Jean-Claude Lavoie
Ibrahim  MohamedIbrahim Mohamed
Ibrahim Mohamed
KPKatryn Paquette
Katryn Paquette
TLThuy Mai Luu
Thuy Mai Luu

14 July 2020 in JAMA
Verified
Journal Article
Closed access
PDF file
IMIsabelle Marcg
Isabelle Marcg
BPBruno Piedboeuf
Bruno Piedboeuf
TLThierry Lacaze-Masmonteil
Thierry Lacaze-Masmonteil
WFWilliam Fraser
William Fraser
BMBenoît Mâsse
Benoît Mâsse
PLPascal Lavoie
Pascal Lavoie
Importance Maternal docosahexaenoic acid (DHA) supplementation may prevent bronchopulmonary dysplasia, but evidence remains inconclusive. Objective To determine whether maternal DHA supplementation during the neonatal period improves bronchopulmonary dysplasia–free survival in breastfed infants born before 29 weeks of gestation. Design, Setting, and Participants Superiority, placebo-controlled randomized clinical trial at 16 Canadian neonatal intensive care units (June 2015-April 2018 with last infant follow-up in July 2018). Lactating women who delivered before 29 weeks of gestation were enrolled within 72 hours of delivery. The trial intended to enroll 800 mothers, but was stopped earlier. Interventions There were 232 mothers (273 infants) assigned to oral capsules providing 1.2 g/d of DHA from randomization to 36 weeks’ postmenstrual age and 229 mothers (255 infants) assigned to placebo capsules. Main Outcomes and Measures The primary outcome was bronchopulmonary dysplasia–free survival in infants at 36 weeks’ postmenstrual age. There were 22 secondary outcomes, including mortality and bronchopulmonary dysplasia. Results Enrollment was stopped early due to concern for harm based on interim data from this trial and from another trial that was published during the course of this study. Among 461 mothers and their 528 infants (mean gestational age, 26.6 weeks [SD, 1.6 weeks]; 253 [47.9%] females), 375 mothers (81.3%) and 523 infants (99.1%) completed the trial. Overall, 147 of 268 infants (54.9%) in the DHA group vs 157 of 255 infants (61.6%) in the placebo group survived without bronchopulmonary dysplasia (absolute difference, –5.0% [95% CI, –11.6% to 2.6%]; relative risk, 0.91 [95% CI, 0.80 to 1.04],P = .18). Mortality occurred in 6.0% of infants in the DHA group vs 10.2% of infants in the placebo group (absolute difference, –3.9% [95% CI, –6.8% to 1.4%]; relative risk, 0.61 [95% CI, 0.33 to 1.13],P = .12). Bronchopulmonary dysplasia occurred in 41.7% of surviving infants in the DHA group vs 31.4% in the placebo group (absolute difference, 11.5% [95% CI, 2.3% to 23.2%]; relative risk, 1.36 [95% CI, 1.07 to 1.73],P = .01). Of 22 prespecified secondary outcomes, 19 were not significantly different. Conclusions and Relevance Among breastfed preterm infants born before 29 weeks of gestation, maternal docosahexaenoic acid supplementation during the neonatal period did not significantly improve bronchopulmonary dysplasia–free survival at 36 weeks’ postmenstrual age compared with placebo. Study interpretation is limited by early trial termination. Trial Registration ClinicalTrials.gov Identifier:NCT02371460

24 October 2015 in Journal of Neonatal-Perinatal Medicine
Verified
Journal Article
Closed access
PDF file
Ibrahim  MohamedIbrahim Mohamed
Ibrahim Mohamed
WEW. Elremaly
W. Elremaly
TRT. Rouleau
T. Rouleau
Jean-Claude LavoieJean-Claude Lavoie
Jean-Claude Lavoie
OBJECTIVES: To assess the effect of early exposure to O2 and parenteral nutrition (PN) on oxidative stress at 36 weeks post-menstrual age (PMA) and on bronchopulmonary dysplasia (BPD) in extremely preterm infants. STUDY DESIGN: A prospective observa

2 June 2022 in Pediatrics
Verified
Journal Article
Closed access
MGMireille Guillot
Mireille Guillot
ASAnne Synnes
Anne Synnes
EPEtienne Pronovost
Etienne Pronovost
MQMosarrat Qureshi
Mosarrat Qureshi
TDThierry Daboval
Thierry Daboval
IMIsabelle Marc
Isabelle Marc
OBJECTIVES: To determine whether maternal supplementation with high-dose docosahexaenoic acid (DHA) in breastfed, very preterm neonates improves neurodevelopmental outcomes at 18 to 22 months’ corrected age (CA). METHODS: Planned follow-up of a randomized, double-blind, placebo-controlled, multicenter trial to compare neurodevelopmental outcomes in breastfed, preterm neonates born before 29 weeks’ gestational age (GA). Lactating mothers were randomized to receive either DHA-rich algae oil or a placebo within 72 hours of delivery until 36 weeks’ postmenstrual age. Neurodevelopmental outcomes were assessed with the Bayley Scales of Infant and Toddler Development third edition (Bayley-III) at 18 to 22 months’ CA. Planned subgroup analyses were conducted for GA (<27 vs ≥27 weeks’ gestation) and sex. RESULTS: Among the 528 children enrolled, 457 (86.6%) had outcomes available at 18 to 22 months’ CA (DHA, N = 234, placebo, N = 223). The mean differences in Bayley-III between children in the DHA and placebo groups were −0.07 (95% confidence interval [CI] −3.23 to 3.10, P = .97) for cognitive score, 2.36 (95% CI −1.14 to 5.87, P = .19) for language score, and 1.10 (95% CI −2.01 to 4.20, P = .49) for motor score. The association between treatment and the Bayley-III language score was modified by GA at birth (interaction P = .07). Neonates born <27 weeks’ gestation exposed to DHA performed better on the Bayley-III language score, compared with the placebo group (mean difference 5.06, 95% CI 0.08–10.03, P = .05). There was no interaction between treatment group and sex. CONCLUSIONS: Maternal DHA supplementation did not improve neurodevelopmental outcomes at 18 to 22 months’ CA in breastfed, preterm neonates, but subgroup analyses suggested a potential benefit for language in preterm neonates born before 27 weeks’ GA.

1 October 2015 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
WEWesam Elremaly
Wesam Elremaly
Ibrahim  MohamedIbrahim Mohamed
Ibrahim Mohamed
TRThérèse Rouleau
Thérèse Rouleau
Jean-Claude LavoieJean-Claude Lavoie
Jean-Claude Lavoie

26 November 2014 in BMJ Case Reports
Verified
Journal Article
Open access
PDF file
Ibrahim  MohamedIbrahim Mohamed
Ibrahim Mohamed
GEGuillaume Ethier
Guillaume Ethier
IGIsabelle Goyer
Isabelle Goyer
PMPhilippe Major
Philippe Major
NDNagib Dahdah
Nagib Dahdah
Rhabdomyoma (RHM) is a benign cardiac tumour usually associated with tuberous sclerosis complex (TSC). Most RHMs are asymptomatic and regress spontaneously during the first years of life. Haemodynamically significant RHMs are classically treated with surgical excision. We present a case of a premature infant, born to a mother having TSC, with a prenatal diagnosis of pulmonary valve atresia and a large ventricular septal defect. Multiple cardiac RHMs were also present, including a large tumour affecting the right ventricular filling. Owing to the prematurity and low birth weight, the infant was inoperable. In this report, we describe our approach to pharmacologically reduce the RHM size using oral everolimus in preparation for a two-ventricle surgical repair of the structural cardiac defect. We also specifically describe the dose of everolimus that was used in this case to achieve therapeutic serum levels, which was seven times lower than the conventional dose applicable for older infants.